# Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

> **NCT03195192** · NA · COMPLETED · sponsor: **Side-Out Foundation** · enrollment: 28 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **OTHER:** biomarker study

## Key facts

- **NCT ID:** NCT03195192
- **Lead sponsor:** Side-Out Foundation
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-09
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2020-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03195192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03195192, "Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03195192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*